This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Phreesia (PHR) Surges 7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Phreesia (PHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Privia Health (PRVA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 500% and 5.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -40% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CareCloud, Inc. (MTBC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareCloud, Inc. (MTBC) delivered earnings and revenue surprises of 29.63% and 5.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 14.29% and 3.93%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 0% and 27.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 9.52% and 2.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Company News for Dec 10, 2021
by Zacks Equity Research
Companies in The News Are: GME,GEF,PHR,NAPA
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of -51.06% and 15.19%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 6th
by Zacks Equity Research
BYND, NVST, FSTR, ZBH, and PHR have been added to the Zacks Rank #5 (Strong Sell) List on December 6, 2021.
Earnings Preview: Phreesia (PHR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for November 29th
by Zacks Equity Research
DVA, NVST, WWD, PHR, and ROAD have been added to the Zacks Rank #5 (Strong Sell) List on November 29, 2021
Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of -118.18% and 8.71%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Phreesia (PHR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 6th
by Zacks Equity Research
DXCM, GP, PHR, RAD, and MAXR have been added to the Zacks Rank #5 (Strong Sell) List on July 6, 2021
Phreesia (PHR) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Phreesia (PHR) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Analysts Estimate Phreesia (PHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of -20.00% and 5.74%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Phreesia (PHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Phreesia (PHR) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Phreesia (PHR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of -21.43% and 7.96%, respectively, for the quarter ended October 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Phreesia (PHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Phreesia (PHR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Phreesia (PHR) Soars: Stock Adds 6.8% in Session
by Zacks Equity Research
Phreesia (PHR) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.